Hikma Pharmaceuticals PLC on Tuesday said it has launched its nasal spray Ryaltris in the US with its partner Glenmark Speciality SA, a subsidiary of Mumbai-based Glenmark Pharmaceuticals Ltd.

The drug is approved by the US Food & Drug Administration for patients aged 12 and above. It treats seasonal allergic rhinitis. Some 60 million Americans have the condition, Hikma said, citing a 2016 study.

‘The launch of Ryaltris is a significant step forward for Hikma in expanding our US nasal spray leadership into branded medicines and advancing our objective of growing our specialty business in the US. Importantly, it will allow us to leverage our strong, existing specialty salesforce already calling on doctors within our specialty portfolio. We look forward to bringing this important new treatment option to the millions of US patients suffering from seasonal allergic rhinitis,’ commented Brian Hoffmann, president of Hikma Generics.

Hikma is London-based, with its operations centre in Amman, Jordan.

Hikma shares were 0.1% higher at 1,337.50 pence each in London on Tuesday afternoon.

Copyright 2022 Alliance News Limited. All Rights Reserved.